Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
You may also be interested in...
Office of Prescription Drug Promotion’s latest study is assessing consumer and physician responses to prescription drug promotions with claims about patient adherence and preference. It is one of 73 research projects OPDP has undertaken.
Association presented oral argument before the Washington State Supreme Court, which certified that drug manufacturers who advertise directly to consumers are not prohibited from using the learned intermediary doctrine as a defense to claims of inadequate warning of a product’s risks.
US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.